Background: Women worldwide die most from breast cancer. To understand cancer prognosis, tumour markers, receptor status, and haematological parameters have been correlated. This study examined the association between breast cancer receptor status (ER, PR, and HER2) and the Mean Platelet Volume (MPV) ratio, an emerging haematological diagnostic. An changed MPV ratio may connect with breast cancer aggressiveness and receptor status. Methods: A retrospective cohort research at SIMS Hospital, Shivamogga, from January 2022 to June 2024. From medical records, 30 breast cancer patients were included. The study included pre-treatment blood tests to obtain clinical demographics, histopathological findings, receptor status (ER, PR, HER2), and MPV values. MPV and MPV ratio were computed for each subject. Chi-square testing and Pearson correlation analysis established the receptor status-MPV ratio relationship.Study results indicate a substantial link between MPV ratio and receptor status, with larger ratios in ER-negative, PR-negative, and HER2-positive breast cancer subtypes among 30 patients. Compared to other receptor status groups, HER2-positive individuals had a substantially higher mean MPV ratio (p < 0.05). MPV ratio did not correlate with tumour grade or stage. Conclusion :This study suggests that MPV ratio might be a cost-effective tool to determine breast cancer aggressiveness, in addition to receptor status. Higher MPV ratios were linked to more aggressive receptor profiles, especially in HER2-positive patients. MPV ratio as a breast cancer biomarker needs more prospective trials to prove its therapeutic value.
Vijaya H Pai (Sat,) studied this question.